Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. The transcript is about Chuy's Holdings, a restaurant chain. They discuss new restaurant openings, development plans, catering program rollout, etc. Key points: They talk about opening new restaurants. They mention that they expect to open 6-9 new restaurants in fiscal 2023, which is the most units they've developed in the last four years. But that's about number of units, not size of each unit. They also mention a new share repurchase program, but that's not about business engagements. They discuss catering program rollout system-wide by end of year. They mention catering is picking up, but no mention of larger catering contracts. They discuss CKO (Chuy's Knockouts) menu items, but that's about menu innovation, not about size of deals. They discuss development plan: "We expect to open two new restaurants in the fourth quarter for a total of three new restaurants openings of fiscal 2022." Then "we are initially expecting to open between six and nine new restaurants" for 2023. That's more units, not larger size per unit. No mention of individual restaurant size, average unit volumes increasing, or larger contracts. They mention "high AUVs" but that's about existing restaurants. They mention "we accelerated our share repurchase program" and new $50 million program, but that's capital allocation, not business engagements. Thus, no evidence of progressively larger size of engagements. They are opening more restaurants, but each restaurant is similar size. No mention of larger sites, bigger projects, etc. Therefore, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.